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Notch signaling is a key developmental pathway that
is subject to frequent genetic and epigenetic pertur-
bations in many different human tumors. Here we
investigate whether long noncoding RNA (lncRNA)
genes, in addition to mRNAs, are key downstream
targets of oncogenic Notch1 in human T cell acute
lymphoblastic leukemia (T-ALL). By integrating
transcriptome profiles with chromatin state maps,
we have uncovered many previously unreported
T-ALL-specific lncRNA genes, a fraction of which
are directly controlled by the Notch1/Rpbjk activator
complex. Finally we have shown that one specific
Notch-regulated lncRNA, LUNAR1, is required for
efficient T-ALL growth in vitro and in vivo due to its
ability to enhance IGF1R mRNA expression and
sustain IGF1 signaling. These results confirm that
lncRNAs are important downstream targets of the
Notch signaling pathway, and additionally they are
key regulators of the oncogenic state in T-ALL.INTRODUCTION
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive he-
matological neoplasm that results from the malignant transfor-
mation of T-lymphocyte progenitors. T-ALL accounts for only
15%–20% of all acute lymphoblastic leukemia (ALL) cases and
is associated with a disproportionate amount of treatment fail-
ures and increased mortality. Although the genetic events lead-
ing to transformation in T-ALL are complex, aberrant NOTCH1
signaling is a unifying feature, with activating mutations found
in more than 50% of cases (Ferrando, 2009; Weng et al.,
2004). Previous efforts by our group and others have aimed atdissecting additional genetic (De Keersmaecker et al., 2013;
Ntziachristos et al., 2012; Zhang et al., 2012) and molecular
(Ferrando et al., 2002; Look, 2004) changes that contribute to
induction of T-ALL. Such efforts have yielded important prog-
nostic tools and a more complete understanding of the molecu-
lar basis of ALL, including the identification of T-ALL oncogenes
(NOTCH1, MYC) and tumor suppressors (FBXW7, CYLD, EZH2,
SUZ12) and the identification and characterization of the leuke-
mia-initiating cell (King et al., 2013). To date, most efforts toward
understanding T-ALL have focused on genetic and epigenetic
alterations, which ultimately impact function of protein-coding
genes. Additionally, several groups have investigated the in-
volvement of noncoding microRNAs (miRNAs) in T-ALL (Fragoso
et al., 2012; Li et al., 2011; Yu et al., 2011); however, the require-
ment of other classes of noncoding RNA for T cell transformation
and maintenance has not been investigated thus far.
Recent evidence has revealed that a large portion of the hu-
man genome is transcriptionally active despite the fact that
only a small portion contains protein-coding genes (Carninci
et al., 2005; Clark et al., 2011; Djebali et al., 2012; Katayama
et al., 2005). This observation has led many to hypothesize that
both human and mouse genomes contain thousands of long
noncoding RNA (lncRNA) genes (Cabili et al., 2011; Guttman
et al., 2009). Although some have suggested that a subset of
lncRNAs are the result of divergent transcription at protein-
coding gene promoters (Almada et al., 2013; Seila et al., 2008),
this does not explain the existence of many intergenic lncRNAs
that do not originate from bidirectional promoters (Cabili et al.,
2011; Sigova et al., 2013). In general, lncRNAs are a heteroge-
neous class of transcripts without any single unifying feature
except for an arbitrary minimum length of 200 nucleotides and
an apparent lack of protein-coding potential (Guttman et al.,
2013; Rinn and Chang, 2012; Ulitsky and Bartel, 2013). Despite
this, lncRNAs have been shown to be important in development
(Boumil and Lee, 2001; Grote et al., 2013; Guttman et al., 2011;
Klattenhoff et al., 2013; Kretz et al., 2013; Loewer et al., 2010;Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc. 593
Rinn et al., 2007) and disease (Gomez et al., 2013; Gupta et al.,
2010; Huarte et al., 2010; Lee et al., 2012; Yildirim et al., 2013)
in many different cell types, suggesting a ubiquitous role in regu-
lation of cellular state. Although the molecular mechanisms by
which lncRNAs act are poorly understood, they have been impli-
cated as regulators of diverse cellular processes including regu-
lation of cell cycle (Hung et al., 2011), RNA stability (Kretz et al.,
2013), and chromatin structure (Gupta et al., 2010; Lee, 2012;
Tsai et al., 2010; Wang et al., 2011b; Yang et al., 2011). Thus,
further efforts toward accurate annotation and functional signif-
icance of lncRNAs will be critical for our understanding of these
processes.
Although several groups have investigated possible roles for
lncRNAs as players in the TP53 tumor-suppressor transcrip-
tional program (Huarte et al., 2010; Hung et al., 2011) and solid
tumors (Du et al., 2013; Prensner et al., 2011; Prensner et al.,
2013; Yang et al., 2013), our overall knowledge of lncRNAs in
cancer, including leukemia, remains extremely limited (Garding
et al., 2013; Lee et al., 2012). Here we have used multiple
genome-wide data sets in order to create the first all-inclusive
lncRNA annotation and mapping in human T-ALL. We have
used this annotation to examine lncRNA expression profiles in
the context of oncogenic NOTCH1 signaling and have identified
Notch-dependent lncRNA expression programs that are deregu-
lated in T-ALL. Finally, we used functional studies to identify a
T-ALL-specific activator lncRNA that has a key role in promoting
tumor maintenance. Altogether these studies provide evidence
to support lncRNAs as key regulators of the pathogenic state
in acute leukemia and may carry important clinical relevance
as biomarkers or future therapeutic targets.
RESULTS
Comprehensive Mapping of lncRNAs in T-ALL
To gain insights into possible functional roles for lncRNAs in
T-ALL, we first sought to create a high-quality map of such tran-
scripts for use in subsequent analyses and functional studies.
We have achieved this goal by utilizing the workflow outlined in
Figure 1A. Briefly, ultra-high-depth RNA-sequencing (RNA-seq)
data sets were generated from multiple human T-ALL cell lines
and primary leukemia samples. These data were then used to
generate the most comprehensive T-ALL transcriptome assem-
bly to date using an ‘‘align then assemble’’ (Trapnell et al., 2010)
approach. To isolate only putative lncRNA genes, we removed all
known protein-coding genes and retained all transcripts previ-
ously reported as lncRNAs or that have not been identified
thus far in other annotation efforts. Single-exon transcripts
were eliminated to focus on products of splicing events. Finally,
because lncRNA transcription has been suggested to occur by a
mechanism very similar to that of coding genes (Guttman et al.,
2009), we removed any transcript that did not display enrich-
ment of promoter-associated histone modifications (H3K4me3,
H3K4me1, H3K27ac). These efforts have yielded a high confi-
dence T-ALL lncRNA annotation comprised of 6,023 isoforms
derived from 1,984 unique gene loci. Out of all of these loci,
46% were identified in the GENCODE v18 lncRNA annotation
(Harrow et al., 2012) (Figure 1B), suggesting the presence of
many novel lncRNAs in T-ALL. Additionally, we have observed594 Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc.that approximately 26% of lncRNAs detected here were ex-
pressed in a divergent orientation with respect to protein-coding
genes, whereas the remaining 74% were true intergenic gene
loci with their own regulatory elements (Figure 1C), and this ratio
of divergent to intergenic lncRNAs is approximately the same in
T-ALL and normal T cell progenitors (Figure S1D). Additionally,
40% of intergenic lncRNAs were identified by GENCODE,
whereas the remaining 60% represent novel lncRNA loci (Fig-
ure S1C available online).
We next examined the expression patterns of our T-ALL
lncRNA catalog over a diverse panel of cell types including
T-ALL, primary T cells, and many other somatic tissues (Human
BodyMap data). In agreement with previous reports (Cabili et al.,
2011), we have observed that average lncRNA expression was
lower than protein-coding gene expression (Figure 1D). Addi-
tionally, putative lncRNAs showed very little protein-coding
potential as measured by the PhyloCSF algorithm (Lin et al.,
2011) (Figure S1A). In agreement with possible roles in regulating
gene expression, many lncRNAs were enriched in RNA from nu-
clear extracts compared to total RNA (Figure S1B). Finally, upon
examination of the 250 most variable lncRNAs, as measured by
quartile coefficient of dispersion, we observed striking specificity
for T-ALL and normal T cells (Figure 1E), which is consistent with
the notion (Guttman et al., 2009) that lncRNA expression is highly
tissue specific. However, many lncRNAs were specifically ex-
pressed in human T-ALL when compared to untransformed
peripheral T cells (Figure 1E), suggesting that T cell transforma-
tion is dynamically changing the lncRNA landscape in this cell
type. Overall, this effort cataloged T-ALL-specific noncoding
RNAs and represents a comprehensive mapping of lncRNA
expression in this aggressive subtype of ALL.
T-ALL-Specific lncRNAs Are Part of the NOTCH1
Oncogenic Network
Given that oncogenic NOTCH1 activity is one of the key features
in T-ALL and NOTCH pathway activity characterizes the vast
majority (>90%) of human T-ALL cases, we reasoned that the
lncRNA expression program in this disease may be influenced
by the NOTCH1/RBPJk transcriptional activator complex.
Upon examination of lncRNA promoters, we noticed a high
density of NOTCH1/RBPJk chromatin immunoprecipitation
sequencing (ChIP-seq) signal at many of these regions (Figures
2A and 2B). Additionally, most lncRNA promoters displayed
high enrichment of H3K4me3, H3K27ac, and RNA polymerase
II (RNA PolII) signal proximal to their TSSs. We also observed a
subset of lncRNAs, which showed co-occupancy of NOTCH1
and ZNF143 (Figures 2A and S2C), a protein that has been pre-
viously reported to co-occupy the genome with Notch, although
its role in gene regulation is unclear (Wang et al., 2011a). We
therefore hypothesized that expression of a subset of lncRNA
genes may be dependent on NOTCH1-mediated signaling. To
test this hypothesis, we used chemical inhibition of the g-secre-
tase complex (Kopan and Ilagan, 2009) to perturb NOTCH1
cleavage and nuclear translocation in two prototypical human
T-ALL cell lines (CUTLL1 and HPB-ALL) and carried out RNA-
seq to measure lncRNA expression following treatment and
NOTCH inhibition. Such approaches have been extensively
used in T-ALL and are proven to specifically target NOTCH1
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Figure 1. The Long Noncoding Transcriptome in T-ALL
(A) A schematic illustration of the procedure used to discover and define lncRNAs in T-ALL.
(B) Venn diagram depicting the overlap between our catalog of T-ALL-associated lncRNAs and those in the Gencode v18 lncRNA collection.
(C) Pie chart representation showing the proportion of T-ALL-associated lncRNAs that are transcribed in a divergent orientation (red) or intergenic (blue) with
respect to protein-coding genes (green, diagram left).
(D) Violin plot of log2 maximum expression values (FPKM) for protein-coding (red) and T-ALL lncRNA (blue) genes. Boxes represent first and third quartiles.
Whiskers are 1.5 times the interquartile range (IQR).
(E) A heatmap representation of the 250 lncRNAswith themost variable (IQR/median) expression across T-ALL, normal T cells, and various other somatic tissues.signaling (Palomero et al., 2006; Weng et al., 2004). Indeed, we
observed that in addition to protein-coding genes, many lncRNA
genes were differentially expressed upon g-secretase inhibitor
(g-SI) treatment compared to vehicle controls (Figures 2C and
S2A), suggesting direct regulation and possible roles down-
stream of NOTCH1 activation in this disease. In agreement
with this notion, we observed that approximately 55% of
lncRNAs whose expression was Notch dependent were also
directly occupied by NOTCH1 (Figure 2D). In support of our hy-
pothesis that NOTCH1 controls the lncRNA transcriptional pro-
gram in T-ALL, we observed that lncRNAs associated with the
top 1,000 most enriched NOTCH1-binding sites were signifi-
cantly downregulated upon administration of g-SI according to
gene set enrichment analysis (GSEA) (Figure 2E). Upon closer
examination of many of these lncRNA loci, we observed strong
NOTCH1/RBPJk-binding sites (Wang et al., 2011a) at both pro-moters and intragenic enhancer elements (Figure S2B, high-
lighted yellow), suggesting direct transcriptional control by
Notch signaling. Together these data suggest the presence of
a Notch-dependent T-ALL lncRNA expression program, mem-
bers of which, we believe, may carry important biological
functions.
To address whether these Notch-regulated lncRNA genes
might be expressed in primary NOTCH1-induced T-ALL, we
measured their expression across ten patient samples that
harbored activating NOTCH1 mutations as well as two primary
human thymus samples, as a matched physiological tissue
with low Notch activation (Ntziachristos et al., 2012). These ana-
lyses yielded a subset of lncRNAs that displayed differential
expression in primary T-ALL compared to normal thymic
T cells (Figure 2F). We also observed that a subset of lncRNAs
are differentially expressed among distinct subtypes of T-ALLCell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc. 595
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as defined by aberrant expression of TLX1 or TLX3 (Figure S2D),
suggesting a possible role in specifying discreet subclasses
within this disease.
Given that activating mutations on NOTCH1 have been
recently discovered in chronic lymphocytic leukemia (CLL) (Fab-
bri et al., 2011), a tumor of the B-lymphocyte compartment, we
hypothesized that Notch-dependent lncRNAs that we have
described in T-ALL might also show similar expression patterns
in CLL. To test this hypothesis, we cultured Notch mutant CLL
cells on OP9-DL1 stromal cells, which express the Notch ligand
delta-like 1 (DL1), and added vehicle control (DMSO) or g-SI fol-
lowed by RNA-seq (Figure 2G). By comparing our T-ALL andCLL
g-SI treatment experiments, we observed that Notch-dependent
changes in lncRNA expression in T-ALL are different from those
in CLL (Figures 2G and 2H). To our surprise, we observed very
little conservation of the Notch-dependent T-ALL lncRNA
expression program in Notch mutant CLL cells, suggesting
that although these two tumors harbor similar oncogenic lesions,
the downstream consequences of Notch activation are distinct.
LUNAR1 Is a NOTCH-Regulated lncRNA Transcript in
Human T-ALL
Because lncRNAs have been previously shown to enhance
expression of nearby genes through cis-regulation (Gomez
et al., 2013; Lai et al., 2013; Ørom et al., 2010), we next asked
whether any of the lncRNAs identified here display a high
Pearson correlation with neighboring protein-coding genes. By
comparing correlation density plots for all coding/lncRNA and
coding/coding gene pairs, we found that in general, lncRNAs
are no more correlated with neighboring genes than their coding
counterparts (Figure 3A). However, because enhancer-like activ-
ity for lncRNAs has been proposed before, we considered all
lncRNAs with at least 0.75 correlation (Figure 3A, shaded area)
with a coding neighbor as candidates for further study as cis-reg-
ulators. From these candidates, we noticed one lncRNA gene,
which we have termed LUNAR1 (leukemia-induced noncoding
activator RNA), that showed high correlation with its coding
neighbor gene the insulin-like growth factor receptor 1 (IGF1R)
(r = 0.77), a gene which has been previously suggested to play
a role in T-ALL (Medyouf et al., 2011). We noted several other
features that made LUNAR1 appear attractive as a candidate.
It was downregulated upon Notch inhibition (Figure 3C), overex-
pressed in primary T-ALL (Figure 3B), and expressed signifi-
cantly higher in T-ALL samples that harbored a Notch mutation
compared to those without mutations (Figure 3D). Additionally,
we also found an enrichment of LUNAR1 in the nucleus (Fig-Figure 2. lncRNAs Are a Component of the Notch1 Transcriptional Ne
(A) Heatmap representation of ChIP-seq signal density for H3K27ac, H3K4me3,
ChIP experiments are from CUTLL1 cells.
(B) Histogram depicting ChIP-seq signal density on all T-ALL lncRNA promoters
(C) Scatterplots showing both lncRNA (green) and protein-coding (orange) genes
(left) and HPBALL (right) cells.
(D) Venn diagram showing the proportion of Notch-occupied lncRNAs whose ex
(E) GSEA enrichment plot showing significant downregulation of lncRNAs assoc
(F) Heatmaps showing top differentially expressed protein-coding (left) and lncR
(G) Expression profiles of lncRNAs that are differentially expressed in response to g
Gray indicates no detectable expression.
(H) Expression fold-change (DMSO/g-SI) in T-ALL (CUTLL1 And HPBALL) and Cure 3E), to a degree similar to that of U1, a component of a small
nuclear ribonucleoprotein (snRNP) splicing complex, which sup-
ported our hypothesis that this transcript may be involved in
gene regulation. By examining the chromatin state at the
LUNAR1 locus, we observed typical features of RNAP2-depen-
dent genes in T-ALL (Figure S3A), as well as a transcriptionally
active state in several related hematopoietic cell types, accord-
ing to the chromHMM algorithm (Figure S3B). Although a tran-
scriptionally active chromatin state was restricted to very few
samples, nearly all of the cell types for which chromHMM data
were available showed signs of active promoter-associated
chromatin structure proximal to the LUNAR1 TSS, indicating a
true transcriptional unit (Figure S3B). Although the LUNAR1
locus shows signs of promoter activity in diverse tissues, its
expression is highly restricted, suggesting that specific factors
are required for its activation. Using standard 50 and 30 rapid
amplification of cDNA ends (RACE) approaches, we were able
to clone a 491-nucleotide transcript containing 4 exons and a
poly(A) tail (FASTA sequence in supplement). In order to address
whether LUNAR1 is indeed noncoding, we utilized the PhyloCSF
algorithm (Lin et al., 2011), which yielded a score of48.12, indi-
cating lack of an open reading frame (ORF) with selective pres-
sure for codon preservation. Additionally, we used PFAM to
translate the RNA sequence in three frames and searched for
known protein domains, of which we found none (not shown).
These data strongly suggest that the LUNAR1 transcript is un-
likely to encode any protein product.
LUNAR1 Expression Is Controlled by an Intronic
Enhancer in the IGF1R Locus
To further study possible functional significance of LUNAR1, we
utilized genome-wide chromosome conformation capture (Hi-C)
in T-ALL cells (CUTLL1) to examine the higher-order chromatin
context in T-ALL (I.A., P.N., and A.T., unpublished data). Similar
to other chromosome capture methods, Hi-C utilizes restriction
enzyme digestion of crosslinked chromatin followed by intramo-
lecular ligation to physically link genomic regions that were in
close spatial proximity to one another (Lieberman-Aiden et al.,
2009). By coupling this method to high-throughput sequencing,
we created a map of 3D chromatin structure in human T-ALL
cells. In doing so, we discovered that LUNAR1 resides in a
500 kb topologically associating domain (Dixon et al., 2012) on
chromosome 15, which also includes neighboring genes
IGF1R and PGPEP1L (Figure 4A). Of these two neighboring
genes, only IGF1R is transcriptionally active; therefore we
reasoned that LUNAR1 might play a role in enhancingtwork
RNAP2, NOTCH1, RBPJk, and ZNF143 centered on lncRNA TSSs ± 5 kb. All
for H3K4me3, RNAP2, and NOTCH1.
whose expression is significantly altered following addition of g-SI in CUTLL1
pression is significantly downregulated in response to g-SI treatment.
iated with the top 1,000 NOTCH1 peaks upon g-SI treatment.
NA (right) genes in primary T-ALL compared to thymic progenitors.
-SI treatment in T-ALL are shown in heatmap either in T-ALL (left) or CLL (right).
LL of all lncRNAs consistently regulated upon Notch inhibition in T-ALL.
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Figure 3. LUNAR1 Is a lncRNA Gene Controlled by NOTCH1 in T-ALL
(A) Correlation density plot showing expression correlation of protein-coding (red) or lncRNA (blue) genes with the nearest coding neighbor.
(B) RNA-seq expression values for LUNAR1 in primary T-ALL and thymic progenitors (left). Overexpression was validated by qPCR (right, top), and overactivation
of Notch signaling was verified by measuring HES1 expression (bottom, right).
(C) qPCR for LUNAR1 following treatment with vehicle (blue) or g-SI (red) in CUTLL1 (left) and HPBALL (right) cells.
(D) qPCR for LUNAR1 in Notch wild-type (WT) versus Notch mutant tumors.
(E) Immunoblot (left) for lamin B and tubulin on cytoplasmic and nuclear fractions from CUTLL1 cells. qPCR (right) for LUNAR1, U1, and GAPDH from RNA
extracted from cytoplasmic and nuclear fractions. * indicates p value < 0.05.
Error bars represent SEM of three experiments.expression of this gene. Closer examination of the LUNAR1/
IGF1R locus revealed the presence of a highly active enhancer
in the last intron of IGF1R, which showed a high degree of occu-
pancy by NOTCH1 (previously reported; Medyouf et al., 2011),
Mediator subunit MED1, histone acetyltransferase P300, RNA
PolII, and the histone reader BRD4 (Figures 4B and S4A), all of
which have been suggested to be hallmarks of active enhancer
elements when located outside of promoter regions (Heintzman
et al., 2009; Rada-Iglesias et al., 2011; Whyte et al., 2013).
In addition to showing enrichment for enhancer-associated
chromatin factors and a chromatin signature characteristic of
active enhancer elements (high H3K4me1, low H3K4me3, high
H3K27ac), we showed that this element is able to drive expres-
sion in a reporter assay in a Notch-dependent manner (Figures
S4B and S4C).
We used chromosome conformation capture (3C) followed by
quantitative PCR (qPCR) to validate our Hi-C findings and iden-
tified a peak of high crosslinking frequency at the IGF1R
enhancer when using a constant HindIII fragment located close
to the LUNAR1 promoter, indicating the presence of a chromatin
loop that places these regions in close physical proximity within598 Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc.the 3D organization of the nucleus (Figure 4C). This finding was
verified using a constant HindIII fragment in the IGF1R enhancer,
suggesting a specific interaction (Figure 4C, lower panel). These
results suggest that this Notch-occupied enhancer element in
the IGF1R locus is able to control LUNAR1 expression through
promoter/enhancer contacts.
LUNAR1 Controls IGF1R Expression and Is Essential for
T-ALL Maintenance
To provide evidence further supporting a more causal relation-
ship between LUNAR1 and IGF1R, we used RNAi to attenuate
LUNAR1 expression. In doing so, we noticed that abrogation
of LUNAR1 led to repression of IGF1R, an effect that was
observed using two independent small hairpin RNAs (shRNAs)
targeting distinct regions of the transcript (Figure 5A). Ectopic
expression of LUNAR1 using retroviral vectors, which integrate
randomly into the genome, did not yield significantly different
expression of IGF1RmRNA (Figure S5A), supporting our hypoth-
esis of a cis-activation mechanism. Additionally, LUNAR1 deple-
tion resulted in a competitive growth disadvantage phenotype in
T-ALL cells (CUTLL1, HPB-ALL) in which the transcript is highly
AB
C
Figure 4. LUNAR1 Is Physically Associated with a Nearby Notch-Occupied Enhancer
(A) Gene track of a 2 Mb region surrounding the LUNAR1 locus including Hi-C interaction density heatmap (red upper panel), ChIP-seq tracks for H3K27ac,
H3K4me1, H3K4me3, MED1, BRD4, P300, NOTCH1, RBPJk, and RNAP2, and RNA-seq track.
(legend continued on next page)
Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc. 599
expressed (Figure 5B) but did not lead to a similar phenotype in
myeloid leukemia cells (HL-60) (Figure S5B), in which LUNAR1
expression is limited, suggesting on-target and T-ALL-specific
effects (Figure 5B). Depletion of LUNAR1 caused a significant
decrease in the number of actively cycling cells as shown by
7AAD staining (Figure S5E). These T-ALL growth effects were
similar to the ones noted when the IGF1R gene was silenced
((Medyouf et al., 2011 and data not shown). In order to further
rule out off-target effects of RNAi, we utilized antisense DNA/
RNA hybrid oligonucleotide (ASO) gene-silencing technology,
which triggers RNase-H-mediated degradation of the target
transcript upon ASO binding. ASO-mediated depletion of
LUNAR1 led to both repression of IGF1R mRNA (Figure S5C)
and a growth retardation phenotype similar to what we observed
with RNAi (Figure S5D).
In order to test the effects of LUNAR1 depletion on tumor
growth in vivo, we performed xenograft assays in which
human T-ALL cells expressing an shRNA targeting LUNAR1
(GFP) or Renilla (mCherry) control were mixed at a 1:1 ratio
and transferred intravenously into sublethally irradiated immu-
nodeficient hosts (Figure 5C). Four weeks after the trans-
plantation, we harvested peripheral tumors and measured by
fluorescence-activated cell sorting (FACS) analysis the relative
contribution of cells harboring each shRNA. Using this assay,
we observed a significant loss of representation of cells in
which LUNAR1 was depleted (Figure 5D), which suggested
that this lncRNA is required for efficient tumor growth both
in vitro and in vivo.
To test whether IGF1R is the relevant target of LUNAR1 as
we have hypothesized, we performed ASO-mediated lncRNA
depletion in T-ALL cells ectopically expressing IGF1R using
retroviral constructs or empty vector control. Following ASO de-
livery, we observed that ectopic expression of IGF1R efficiently
rescued the growth defects observed following LUNAR1 deple-
tion (Figure 5E), suggesting that IGF1R is indeed a key target of
this lncRNA.
To characterize the overall cellular response to LUNAR1
silencing, we performed global gene-expression analysis
(RNA-seq) in T-ALL cells following LUNAR1 depletion with two
independent shRNAs. For comparison, we also performed ex-
periments in which we blocked IGF1 signaling using pharmaco-
logical inhibition (BMS-536924) followed by RNA-seq. The
outcome of these studies was striking as we noted significant
repression of IGF1RmRNA, in agreement with our qPCR studies
(Figure 5A). We also identified a subset of genes, which were
similarly regulated following either IGF1R inhibition or LUNAR1
depletion (Figure 5F), suggesting that this lncRNA promotes
IGF1 signaling by transcriptional regulation of IGF1R. Finally,
using GSEA, we found significant enrichment for gene sets con-
taining genes significantly downregulated upon IGF1 inhibition in
T-ALL (Figure S5F) and other publicly available gene sets con-
taining targets of IGF1/2 (Figure S5F).(B) Gene track view of an approximately 150 kb region that contains LUNAR1 (high
(highlighted yellow, left).
(C) Relative crosslinking frequency as measured by 3C-qPCR using a constant p
enhancer (bottom). Crosslinking frequency is relative to a negative region (green
Error bars indicate the ± SEM of three experiments.
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Gene Activity
In order to test whether LUNAR1 displayed intrinsic ability to pro-
mote gene activity, we used the Gal4-lN/BoxB system to tether
this lncRNA to a heterologous reporter promoter (Li et al., 2013;
Wang et al., 2011b). In this system, the BoxB RNA stem loop is
fused to a lncRNA, which allows it to bind specifically and with
high affinity to the phage l N-peptide (lN). By fusing lN to the
DNA-binding domain of the yeast Gal4 protein, a BoxB-tagged
lncRNA can be tethered to UAS DNA sequences (Figure 6A).
We cotransfected vector containing the Gal4-lN fusion with
either BoxB-tagged LUNAR1 or known activator lncRNA
HOTTIP into HEK293 cells stably expressing five UAS sites up-
stream of a TK-luciferase reporter gene (Vaquero et al., 2004).
Upon transfection, we could detect binding of theGal4-lN fusion
at the reporter promoter as expected (Figure 6B). Tethering
LUNAR1 to this reporter gene stimulated transcription of the re-
porter to a similar degree as HOTTIP (Figure 6C). Additionally,
ASO-mediated depletion of LUNAR1 (Figure 6D) significantly
reduced this stimulatory effect compared to a nontargeting
ASO (Figure 6E), suggesting that molecules of LUNAR1 are func-
tionally important for the stimulation of transcription seen here.
In order to investigate the mechanism by which endogenous
LUNAR1 promotes transcriptional activity of the IGF1R gene,
we performed chromatin studies following depletion of the
lncRNA in T-ALL cells. Because we hypothesized that LUNAR1
might be an important component of the intronic IGF1R
enhancer, we reasoned that depletion of this transcript might in-
fluence chromatin state or occupancy of one of the activators at
that locus. Following depletion of LUNAR1, we observed a signif-
icant reduction in Mediator complex (MED1 and MED12) and
RNA PolII occupancy at both the IGF1R enhancer and the
LUNAR1 promoter (Figures 7A and 7B). Additionally, we ob-
served significant loss of RNA PolII binding at the IGF1R pro-
moter (not shown). We did not observe any changes in NOTCH1
binding or levels of histone modifications H3K27ac, H3K4me1,
or H3K4me3 at these loci (Figures 7A and 7B), suggesting spe-
cific destabilization of Mediator and RNAP2 following LUNAR1
depletion. We observed no changes in the status of any of these
factors at the ACTB promoter, again suggesting a locus-specific
effect. Because depletion of LUNAR1 led to locus-specific loss
of Mediator and RNA PolII binding, we hypothesized that
LUNAR1 RNA might co-occupy the chromatin in those loci.
Using chromatin isolation by RNA purification (ChIRP), we
were able to efficiently retrieve LUNAR1 RNA (Figure 7D) and
observed specific enrichment of LUNAR1 at the IGF1R enhancer
and LUNAR1 promoter (Figure 7E), which supports amechanism
by which LUNAR1 exploits chromatin configuration to reach its
targets (Figure 7F) (Engreitz et al., 2013). Together these data
suggest that the intronic IGF1R enhancer activates LUNAR1,
which then co-occupies the element and further recruits Medi-
ator in order to sustain full activation of the IGF1R promoter.lighted yellow, right) and a Notch-occupied enhancer in the last intron of IGF1R
rimer in a HindIII fragment at the LUNAR1 TSS (top) or at the Notch-occupied
).
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Figure 5. LUNAR1 Regulates T-ALL Proliferation by Enhancing IGF1R Expression
(A) qPCR showing expression of LUNAR1 (blue) and IGF1R (yellow) in the presence of shRNAs targeting Renilla or LUNAR1.
(B) Line graphs showing relative contribution from T-ALL cells expressing shRNAs against LUNAR1 grown in competition with cells expressing a nontargeting
shRNA.
(legend continued on next page)
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Figure 6. LUNAR1 Is Able to Stimulate Tran-
scription of a Reporter Gene
(A) Illustration describing the BoxB Gal4-lN RNA
tethering system used.
(B) ChIP assay for Gal4-DBD at the reporter gene
promoter.
(C) Luciferase reporter activity in experiments
where BoxB-tagged LUNAR1 (blue) or HOTTIP
(yellow) were cotransfected with Gal4-lN.
(D) qPCR following ASO knockdown of LUNAR1 in
luciferase assay.
(E) Reporter assay showing relative reporter gene
activity when BoxB-LUNAR1 was cotransfected
with either nontargeting (blue) or LUNAR1-specific
(yellow) ASOs.
Error bars represent SEM of at least three ex-
periments. * indicates p value < 0.05. ** indicates
p value < 0.01.These studies revealed LUNAR1 as a regulator of IGF1
signaling and T-ALL cell growth, identifying a putative lncRNA
that could be therapeutically targeted in acute leukemia. Addi-
tionally we provide further evidence for the ubiquitous presence
and functional importance of lncRNAs in human disease and
provide evidence that lncRNAs, in addition to protein-coding
genes, are key downstream targets of Notch signaling.
DISCUSSION
The last decades were characterized by an extensive delineation
of oncogenic pathways in different cancer types, focusing on
protein-coding transcripts and more recently on noncoding
miRNA networks. However, very little was known on expression
patterns and biological significance of lncRNAs in human
tumorigenesis. Also, very little was reported on the regulation
of such lncRNAs by well-described oncogenic signaling path-
ways. Here we map the expression of lncRNAs in acute leuke-
mia, using T-ALL, a disease characterized by activation of the
NOTCH pathway. Using integration of whole transcriptome anal-
ysis and genome-wide chromatin state maps, we systematically
identified T-ALL-specific lncRNA genes and characterized non-
coding transcripts regulated directly by the binding and the acti-(C) Illustration describing in vivo xenograft competition assay.
(D) Ratio of mean fluorescence intensity (MFI) on day 28:day 0.
(E) Line graphs showing relative cell number (targeting/Scr) for cells expressing exogenous IGF1R (blue) or
(F) Genome-wide measurement of differentially expressed genes following pharmacological inhibition of IGF
Error bars represent ± SEM of at least three experiments. * indicates p value < 0.05. ** indicates p value < 0
602 Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc.vation of NOTCH1. To further suggest
biological significance, we used RNA-
seq of primary human T-ALL, character-
ized by NOTCH1 and FBXW7 mutations
(leading to NOTCH activation), and were
able to prove the existence of T-ALL-spe-
cific lncRNAs also regulated by NOTCH1
activity, suggesting that NOTCH signaling
is able to shape not only the protein-
coding but also the lncRNA landscape inthis disease. These results suggest that—at least a fraction
of—the NOTCH1-triggered oncogenic activity could be due to
its ability to regulate such noncoding transcripts.
To test this assumption, we have selected LUNAR1, a lncRNA
that shows T-ALL-specific Notch-dependent expression pat-
terns, is localized in the nucleus, and displays high correlation
with IGF1R, a receptor previously suggested to play a role in
T-ALL (Medyouf et al., 2011). Using assays that can map chro-
mosome conformation and looping, we were able to show an
interaction between the TSS of LUNAR1 and an enhancer
element located within the IGF1R locus, characterized by
NOTCH1 binding (Figures 4 and S4). To prove the connection
between LUNAR1 expression and IGF1R, we were able to
demonstrate that the silencing of this lncRNA led to a significant
downregulation of IGF1R expression in T-ALL cells and dimin-
ished IGF1 pathway activity. Although it is possible that IGF1R
is not the sole target of LUNAR1, we propose that one of its
key functions is to modulate IGF1 signaling in T-ALL by regula-
tion transcription of the receptor gene (Figure 5).
Using various assays (Figures 6 and 7), we have provided
evidence that LUNAR1 belongs to a subclass of enhancer-like
lncRNAs, which have been reported previously (Lai et al.,
2013; Ørom et al., 2010; Wang et al., 2011b; Yang et al., 2014).empty vector (red) treated with ASO.
1R or LUNAR1 knockdown.
.01.
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Figure 7. LUNAR1 Modulates Mediator and RNA PolII Binding at the IGF1R Enhancer
(A–C) ChIP assays for MED1, MED12, RNAP2, NOTCH1, H3K27ac, H3K4me1, and H3K4me3 in T-ALL cells harboring nontargeting (blue) or LUNAR1-specific
shRNAs followed by locus-specific qPCR at (A) IGF1R enhancer, (B) LUNAR1 promoter, or (C) ACTB promoter.
(D) Percent recovery of LUNAR1 following ChIRP.
(E) ChIRP assay using probes targeting LUNAR1 (blue) or LacZ (yellow) followed by qPCR at the IGF1R enhancer, LUNAR1 promoter, and ACTB promoter.
(F) A model for cis-regulation of gene expression by LUNAR1.
Error bars represent SEM of at least three experiments. * indicates p value < 0.05. ** indicates p value < 0.01.
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Among enhancer-like lncRNAs, there appear to be two distinct
functional mechanisms at play. One mechanism involves
lncRNA-dependent recruitment ofWDR5-containingmethyltras-
ferase complexes, which catalyzedmethylation of the tails of his-
tone 3 on lysine 4 (Gomez et al., 2013; Wang et al., 2011b; Yang
et al., 2014). A secondmechanism involves stabilization of Medi-
ator complexes and RNA PolII at enhancer elements (Lai et al.,
2013). Based on chromatin experiments following LUNAR1
depletion, this lncRNA is most likely functionally similar to the
noncoding RNA activators (nc-RNA-a) that have been described
previously (Lai et al., 2013; Ørom et al., 2010). Because there are
currently no methods for predicting lncRNA function based on
sequence alone, we believe our results represent an incremental,
yet important contribution to the overall understanding of
lncRNA biology.
Our mapping of lncRNAs in human T-ALL opens the possibility
that such previously uncharacterized transcripts are key modu-
lators of cellular transformation, through their interaction with
oncogenic and tumor suppressor programs in leukemia. Addi-
tionally, the suggested (and reported also here) tissue and cell-
type specificity of lncRNA expression would suggest that such
transcripts could be powerful and specific biomarkers used to
categorize cancer subtypes and stratify patients for clinical trials
and therapeutic protocols.
EXPERIMENTAL PROCEDURES
RNA Extraction Preparation for Next-Generation Sequencing
Total RNA was extracted from samples using the RNeasy Plus mini kit (Life
Technologies, Carlsbad, CA, USA). Samples were then subject to poly(A)
selection (Figures 1E, 5F, and 5G only) using oligo-dT beads (Life Technolo-
gies) or rRNA removal (all other samples) using the Ribo-Zero kit (Epicenter,
Madison,WI, USA), according to themanufacturer’s instructions. The resulting
RNA samples were then used as input for library construction using the dUTP
method as described (Parkhomchuk et al., 2009). RNA libraries were then
sequenced on the Illumina HiSeq 2000 or 2500 using 50 bp paired-end reads.
RNA-Sequencing Data Analysis
All RNA-seq data were aligned to hg19 using TopHat (Trapnell et al., 2009) v1.4
with default parameters. We used Cuffdiff (Trapnell et al., 2010) v1.3 for all
differential expression (DE) analyses with our custom annotation consisting
of RefSeq entries plus T-ALL lncRNAs as described below. In all DE tests, a
gene was considered significant if the q value was less than 0.05 (Cuffdiff
default).
lncRNA Discovery
We sequenced two samples from T-ALL cell lines (CUTLL1 and HPBALL), two
primary human thymus samples to ultra-high depth (>200 million mate pairs
each), ten primary pediatric T-ALL samples (60–80 million mate pairs each),
and data generated by the Roadmap Epigenomics project for Naive CD4+
and CD8+ T cells to be used for ab initio transcriptome assembly with Cufflinks
v1.3. Briefly, Cufflinks was run with the following options: -u, -N, -g (RefSeq
GTF file provided as guide), and -M (rRNA and 7SK RNA mask file provided).
We generated transcriptome assemblies for each of these samples separately
and then used Cuffmerge to combine all annotations. For all subsequent
filtering and processing steps, please see the Extended Experimental
Procedures.
ChIP
The following antibodies were used for ChIP experiments: Notch1 C-20 (Santa
Cruz sc-6014), Med1 (Bethyl, A300-793A), Med12 (Bethyl, A300-774A), RNA
PolII N-20 (Santa Cruz, sc-899), H3K4me1 (Abcam, ab8895), H3K4me3 (Active
Motif, 39159), and H3K27ac (Abcam, ab4729). ChIP assays were performed604 Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc.essentially as described previously (Whyte et al., 2013). See the Extended
Experimental Procedures for a detailed description of ChIP assay.
ChIRP
ChIRP assays were performed as described (Chu et al., 2011) with the
following modifications. Cells were double crosslinked first with 2 mM EGS
for 45 min at room temperature and washed twice with ice-cold PBS. Cells
were then further cross-liked with 3% formaldehyde for 30 min at room
temperature, and reaction was stopped by the addition of 0.125M glycine
followed by two more washes in PBS. Crosslinked cells were then lysed
in sonication buffer (see ChIP method) supplemented with SUPERaseIn
(Life technologies), and chromatin was sheared exactly as for ChIP assays.
Chromatin was cleared by centrifugation and supernatant was used for ChIRP
reactions. All following steps were performed exactly as described by Chu
et al. with the following exceptions: in the hybridization buffer, 1% Triton
with 0.1% SDS was used instead of 1% SDS, and in the wash buffer, SDS
concentration was lowered from 0.5% to 0.1%. Probes used for ChIRP assays
are listed in Table S2.
Chromosome Conformation Capture
3C experiments were performed essentially as described previously (Hage`ge
et al., 2007). Please see the Extended Experimental Procedures for a detailed
description of this method.ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession number for the RNA-Seq data
reported in this paper is GSE57982.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and four tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.05.049.
ACKNOWLEDGMENTS
We would like to thank the members of the I.A. laboratory for helpful discus-
sions throughout the duration of the project. We thank Drs. Danny Reinberg,
Roberto Bonasio, Howard Chang, and Adam Schmidtt for valuable discus-
sions, technical advice, and reagents. We thank Drs. Sergei Koralov and
Jane Skok for their continued support and helpful insight. We are grateful
to Dr. Mignon Loh and the Children’s Oncology Group for providing
patient samples and to Dr. A. Heguy and the NYU Genome Technology
Center (supported in part by NIH/NCI P30 CA016087-30 grant) for assistance
with sequencing experiments. Research is supported by the Chair’s Grant
U10 CA98543 and Human Specimen Banking Grant U24 CA114766 of the
Children’s Oncology Group from the National Cancer Institute, National Insti-
tutes of Health (Bethesda, MD, USA). I.A. was supported by the National
Institutes of Health (1RO1CA133379, 1RO1CA105129, 1RO1CA149655,
5RO1CA173636, 5RO1CA169784, and 1RO1GM088847). I.A. was also
supported by the William Lawrence and Blanche Hughes Foundation, The
Leukemia & Lymphoma Society (TRP#6340-11, LLS#6373-13), The Chemo-
therapy Foundation, The Irma T. Hirschl Trust, The V Foundation for Cancer
Research, and the St. Baldrick’s Foundation. T.T. is supported by NIH
training grants 5T32CA009161-37 and 5T32GM0072-38. I.A. is a Howard
Hughes Medical Institute Early Career Scientist. A.T. carried out a portion
of this work while at the Computational Biology Center, IBM Research
(Yorktown Heights, NY, USA). P.N. is supported by an American Society of
Hematology fellowship.
Received: August 26, 2013
Revised: March 23, 2014
Accepted: May 16, 2014
Published: July 31, 2014
REFERENCES
Almada, A.E., Wu, X., Kriz, A.J., Burge, C.B., and Sharp, P.A. (2013). Promoter
directionality is controlled by U1 snRNP and polyadenylation signals. Nature
499, 360–363.
Boumil, R.M., and Lee, J.T. (2001). Forty years of decoding the silence in
X-chromosome inactivation. Hum. Mol. Genet. 10, 2225–2232.
Cabili, M.N., Trapnell, C., Goff, L., Koziol, M., Tazon-Vega, B., Regev, A., and
Rinn, J.L. (2011). Integrative annotation of human large intergenic noncoding
RNAs reveals global properties and specific subclasses. Genes Dev. 25,
1915–1927.
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N.,
Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al.; FANTOM Consortium;
RIKEN Genome Exploration Research Group and Genome Science Group
(Genome Network Project Core Group) (2005). The transcriptional landscape
of the mammalian genome. Science 309, 1559–1563.
Chu, C., Qu, K., Zhong, F.L., Artandi, S.E., and Chang, H.Y. (2011). Genomic
maps of long noncoding RNA occupancy reveal principles of RNA-chromatin
interactions. Mol. Cell 44, 667–678.
Clark, M.B., Amaral, P.P., Schlesinger, F.J., Dinger, M.E., Taft, R.J., Rinn, J.L.,
Ponting, C.P., Stadler, P.F., Morris, K.V., Morillon, A., et al. (2011). The reality of
pervasive transcription. PLoS Biol. 9, e1000625, discussion e1001102.
De Keersmaecker, K., Atak, Z.K., Li, N., Vicente, C., Patchett, S., Girardi, T.,
Gianfelici, V., Geerdens, E., Clappier, E., Porcu, M., et al. (2013). Exome
sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and
RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186–190.
Dixon, J.R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J.S., and
Ren, B. (2012). Topological domains in mammalian genomes identified by
analysis of chromatin interactions. Nature 485, 376–380.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A.,
Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of
transcription in human cells. Nature 489, 101–108.
Du, Z., Fei, T., Verhaak, R.G., Su, Z., Zhang, Y., Brown, M., Chen, Y., and Liu,
X.S. (2013). Integrative genomic analyses reveal clinically relevant long non-
coding RNAs in human cancer. Nat. Struct. Mol. Biol. 20, 908–913.
Engreitz, J.M., Pandya-Jones, A., McDonel, P., Shishkin, A., Sirokman, K.,
Surka, C., Kadri, S., Xing, J., Goren, A., Lander, E.S., et al. (2013). The Xist
lncRNA exploits three-dimensional genome architecture to spread across
the X chromosome. Science 341, 1237973.
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A.,
Fangazio, M., Capello, D., Monti, S., et al. (2011). Analysis of the chronic lym-
phocytic leukemia coding genome: role of NOTCH1 mutational activation.
J. Exp. Med. 208, 1389–1401.
Ferrando, A.A. (2009). The role of NOTCH1 signaling in T-ALL. Hematology
(Am. Soc. Hematol. Educ. Program), 353–361.
Ferrando, A.A., Neuberg, D.S., Staunton, J., Loh, M.L., Huard, C., Raimondi,
S.C., Behm, F.G., Pui, C.H., Downing, J.R., Gilliland, D.G., et al. (2002).
Gene expression signatures define novel oncogenic pathways in T cell acute
lymphoblastic leukemia. Cancer Cell 1, 75–87.
Fragoso, R., Mao, T., Wang, S., Schaffert, S., Gong, X., Yue, S., Luong, R., Min,
H., Yashiro-Ohtani, Y., Davis, M., et al. (2012). Modulating the strength and
threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet. 8,
e1002855.
Garding, A., Bhattacharya, N., Claus, R., Ruppel, M., Tschuch, C., Filarsky, K.,
Idler, I., Zucknick, M., Caudron-Herger, M., Oakes, C., et al. (2013). Epigenetic
upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downre-
gulation of a gene cluster that targets NF-kB. PLoS Genet. 9, e1003373.
Gomez, J.A., Wapinski, O.L., Yang, Y.W., Bureau, J.F., Gopinath, S., Monack,
D.M., Chang, H.Y., Brahic, M., and Kirkegaard, K. (2013). The NeST long
ncRNA controls microbial susceptibility and epigenetic activation of the
interferon-g locus. Cell 152, 743–754.
Grote, P., Wittler, L., Hendrix, D., Koch, F., Wa¨hrisch, S., Beisaw, A., Macura,
K., Bla¨ss, G., Kellis, M., Werber, M., and Herrmann, B.G. (2013). The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall devel-
opment in the mouse. Dev. Cell 24, 206–214.
Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., Tsai,
M.C., Hung, T., Argani, P., Rinn, J.L., et al. (2010). Long non-coding RNA
HOTAIR reprograms chromatin state to promote cancer metastasis. Nature
464, 1071–1076.
Guttman,M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M.,
Zuk, O., Carey, B.W., Cassady, J.P., et al. (2009). Chromatin signature reveals
over a thousand highly conserved large non-coding RNAs inmammals. Nature
458, 223–227.
Guttman, M., Donaghey, J., Carey, B.W., Garber, M., Grenier, J.K., Munson,
G., Young, G., Lucas, A.B., Ach, R., Bruhn, L., et al. (2011). lincRNAs act in
the circuitry controlling pluripotency and differentiation. Nature 477, 295–300.
Guttman, M., Russell, P., Ingolia, N.T., Weissman, J.S., and Lander, E.S.
(2013). Ribosome profiling provides evidence that large noncoding RNAs do
not encode proteins. Cell 154, 240–251.
Hage`ge, H., Klous, P., Braem, C., Splinter, E., Dekker, J., Cathala, G., de Laat,
W., and Forne´, T. (2007). Quantitative analysis of chromosome conformation
capture assays (3C-qPCR). Nat. Protoc. 2, 1722–1733.
Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocin-
ski, F., Aken, B.L., Barrell, D., Zadissa, A., Searle, S., et al. (2012). GENCODE:
the reference human genome annotation for The ENCODE Project. Genome
Res. 22, 1760–1774.
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp,
L.F., Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifi-
cations at human enhancers reflect global cell-type-specific gene expression.
Nature 459, 108–112.
Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M.J., Kenzelmann-
Broz, D., Khalil, A.M., Zuk, O., Amit, I., Rabani, M., et al. (2010). A large inter-
genic noncoding RNA induced by p53 mediates global gene repression in the
p53 response. Cell 142, 409–419.
Hung, T., Wang, Y., Lin, M.F., Koegel, A.K., Kotake, Y., Grant, G.D., Horlings,
H.M., Shah, N., Umbricht, C., Wang, P., et al. (2011). Extensive and coordi-
nated transcription of noncoding RNAs within cell-cycle promoters. Nat.
Genet. 43, 621–629.
Imakaev, M., Fudenberg, G., McCord, R.P., Naumova, N., Goloborodko, A.,
Lajoie, B.R., Dekker, J., and Mirny, L.A. (2012). Iterative correction of Hi-C
data reveals hallmarks of chromosome organization. Nat. Methods 9, 999–
1003.
Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura,
M., Nishida, H., Yap, C.C., Suzuki, M., Kawai, J., et al.; RIKEN Genome Explo-
ration Research Group; Genome Science Group (Genome Network Project
Core Group); FANTOM Consortium (2005). Antisense transcription in the
mammalian transcriptome. Science 309, 1564–1566.
King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P.,
Aranda-Orgilles, B., Perez-Garcia, A., Shi, J., Vakoc, C., et al. (2013). The ubiq-
uitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating
MYC stability. Cell 153, 1552–1566.
Klattenhoff, C.A., Scheuermann, J.C., Surface, L.E., Bradley, R.K., Fields, P.A.,
Steinhauser, M.L., Ding, H., Butty, V.L., Torrey, L., Haas, S., et al. (2013).
Braveheart, a long noncoding RNA required for cardiovascular lineage
commitment. Cell 152, 570–583.
Kopan, R., and Ilagan, M.X. (2009). The canonical Notch signaling pathway:
unfolding the activation mechanism. Cell 137, 216–233.
Kretz, M., Siprashvili, Z., Chu, C.,Webster, D.E., Zehnder, A., Qu, K., Lee, C.S.,
Flockhart, R.J., Groff, A.F., Chow, J., et al. (2013). Control of somatic tissue dif-
ferentiation by the long non-coding RNA TINCR. Nature 493, 231–235.
Lai, F., Orom, U.A., Cesaroni, M., Beringer, M., Taatjes, D.J., Blobel, G.A., and
Shiekhattar, R. (2013). Activating RNAs associate with Mediator to enhance
chromatin architecture and transcription. Nature 494, 497–501.
Lee, C.S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D.E., Armstrong, R.,
Weng, W.K., Aros, C.J., Mah, A., Chen, R.O., et al. (2012). TranscriptomeCell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc. 605
sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-
associated lncRNAs and novel transcripts. Blood 120, 3288–3297.
Lee, J.T. (2012). Epigenetic regulation by long noncoding RNAs. Science 338,
1435–1439.
Li, W., Notani, D., Ma, Q., Tanasa, B., Nunez, E., Chen, A.Y., Merkurjev, D.,
Zhang, J., Ohgi, K., Song, X., et al. (2013). Functional roles of enhancer
RNAs for oestrogen-dependent transcriptional activation. Nature 498,
516–520.
Li, X., Sanda, T., Look, A.T., Novina, C.D., and von Boehmer, H. (2011).
Repression of tumor suppressor miR-451 is essential for NOTCH1-induced
oncogenesis in T-ALL. J. Exp. Med. 208, 663–675.
Lieberman-Aiden, E., van Berkum, N.L., Williams, L., Imakaev, M., Ragoczy,
T., Telling, A., Amit, I., Lajoie, B.R., Sabo, P.J., Dorschner, M.O., et al.
(2009). Comprehensive mapping of long-range interactions reveals folding
principles of the human genome. Science 326, 289–293.
Lin, M.F., Jungreis, I., and Kellis, M. (2011). PhyloCSF: a comparative geno-
mics method to distinguish protein coding and non-coding regions. Bioinfor-
matics 27, i275–i282.
Loewer, S., Cabili, M.N., Guttman, M., Loh, Y.H., Thomas, K., Park, I.H.,
Garber, M., Curran, M., Onder, T., Agarwal, S., et al. (2010). Large intergenic
non-coding RNA-RoR modulates reprogramming of human induced pluripo-
tent stem cells. Nat. Genet. 42, 1113–1117.
Look, A.T. (2004). Molecular pathways in T-cell acute lympho-blastic leukemia:
ramifications for therapy. Clin. Adv. Hematol. Oncol. 2, 779–780.
Medyouf, H., Gusscott, S., Wang, H., Tseng, J.C., Wai, C., Nemirovsky, O.,
Trumpp, A., Pflumio, F., Carboni, J., Gottardis, M., et al. (2011). High-level
IGF1R expression is required for leukemia-initiating cell activity in T-ALL and
is supported by Notch signaling. J. Exp. Med. 208, 1809–1822.
Ntziachristos, P., Tsirigos, A., Van Vlierberghe, P., Nedjic, J., Trimarchi, T.,
Flaherty, M.S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al.
(2012). Genetic inactivation of the polycomb repressive complex 2 in T cell
acute lymphoblastic leukemia. Nat. Med. 18, 298–301.
Ørom, U.A., Derrien, T., Beringer, M., Gumireddy, K., Gardini, A., Bussotti, G.,
Lai, F., Zytnicki, M., Notredame, C., Huang, Q., et al. (2010). Long noncoding
RNAs with enhancer-like function in human cells. Cell 143, 46–58.
Palomero, T., Barnes, K.C., Real, P.J., Glade Bender, J.L., Sulis, M.L., Murty,
V.V., Colovai, A.I., Balbin, M., and Ferrando, A.A. (2006). CUTLL1, a novel hu-
man T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1
activation and high sensitivity to gamma-secretase inhibitors. Leukemia 20,
1279–1287.
Parkhomchuk, D., Borodina, T., Amstislavskiy, V., Banaru, M., Hallen, L.,
Krobitsch, S., Lehrach, H., and Soldatov, A. (2009). Transcriptome analysis
by strand-specific sequencing of complementary DNA. Nucleic Acids Res.
37, e123.
Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner,
J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. (2011).
Transcriptome sequencing across a prostate cancer cohort identifies
PCAT-1, an unannotated lincRNA implicated in disease progression. Nat.
Biotechnol. 29, 742–749.
Prensner, J.R., Iyer, M.K., Sahu, A., Asangani, I.A., Cao, Q., Patel, L., Vergara,
I.A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013). The long noncoding
RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the
SWI/SNF complex. Nat. Genet. 45, 1392–1398.
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., and
Wysocka, J. (2011). A unique chromatin signature uncovers early develop-
mental enhancers in humans. Nature 470, 279–283.
Rinn, J.L., and Chang, H.Y. (2012). Genome regulation by long noncoding
RNAs. Annu. Rev. Biochem. 81, 145–166.
Rinn, J.L., Kertesz, M., Wang, J.K., Squazzo, S.L., Xu, X., Brugmann, S.A.,
Goodnough, L.H., Helms, J.A., Farnham, P.J., Segal, E., and Chang, H.Y.606 Cell 158, 593–606, July 31, 2014 ª2014 Elsevier Inc.(2007). Functional demarcation of active and silent chromatin domains in hu-
man HOX loci by noncoding RNAs. Cell 129, 1311–1323.
Seila, A.C., Calabrese, J.M., Levine, S.S., Yeo, G.W., Rahl, P.B., Flynn, R.A.,
Young, R.A., and Sharp, P.A. (2008). Divergent transcription from active pro-
moters. Science 322, 1849–1851.
Sigova, A.A., Mullen, A.C., Molinie, B., Gupta, S., Orlando, D.A., Guenther,
M.G., Almada, A.E., Lin, C., Sharp, P.A., Giallourakis, C.C., and Young, R.A.
(2013). Divergent transcription of long noncoding RNA/mRNA gene pairs in
embryonic stem cells. Proc. Natl. Acad. Sci. USA 110, 2876–2881.
Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice
junctions with RNA-Seq. Bioinformatics 25, 1105–1111.
Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren,
M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly
and quantification by RNA-Seq reveals unannotated transcripts and isoform
switching during cell differentiation. Nat. Biotechnol. 28, 511–515.
Tsai, M.C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J.K., Lan, F., Shi,
Y., Segal, E., and Chang, H.Y. (2010). Long noncoding RNA as modular scaf-
fold of histone modification complexes. Science 329, 689–693.
Ulitsky, I., and Bartel, D.P. (2013). lincRNAs: genomics, evolution, and mech-
anisms. Cell 154, 26–46.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., and
Reinberg, D. (2004). Human SirT1 interacts with histone H1 and promotes for-
mation of facultative heterochromatin. Mol. Cell 16, 93–105.
Wang, H., Zou, J., Zhao, B., Johannsen, E., Ashworth, T., Wong, H., Pear,
W.S., Schug, J., Blacklow, S.C., Arnett, K.L., et al. (2011a). Genome-wide
analysis reveals conserved and divergent features of Notch1/RBPJ binding
in human and murine T-lymphoblastic leukemia cells. Proc. Natl. Acad. Sci.
USA 108, 14908–14913.
Wang, K.C., Yang, Y.W., Liu, B., Sanyal, A., Corces-Zimmerman, R., Chen, Y.,
Lajoie, B.R., Protacio, A., Flynn, R.A., Gupta, R.A., et al. (2011b). A long non-
coding RNA maintains active chromatin to coordinate homeotic gene expres-
sion. Nature 472, 120–124.
Weng, A.P., Ferrando, A.A., Lee, W., Morris, J.P., 4th, Silverman, L.B., San-
chez-Irizarry, C., Blacklow, S.C., Look, A.T., and Aster, J.C. (2004). Activating
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science
306, 269–271.
Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H.,
Rahl, P.B., Lee, T.I., and Young, R.A. (2013). Master transcription factors and
mediator establish super-enhancers at key cell identity genes. Cell 153,
307–319.
Yang, L., Lin, C., Liu,W., Zhang, J., Ohgi, K.A., Grinstein, J.D., Dorrestein, P.C.,
and Rosenfeld, M.G. (2011). ncRNA- and Pc2 methylation-dependent gene
relocation between nuclear structures mediates gene activation programs.
Cell 147, 773–788.
Yang, L., Lin, C., Jin, C., Yang, J.C., Tanasa, B., Li, W., Merkurjev, D., Ohgi,
K.A., Meng, D., Zhang, J., et al. (2013). lncRNA-dependent mechanisms of
androgen-receptor-regulated gene activation programs. Nature 500, 598–602.
Yang, Y.W., Flynn, R.A., Chen, Y., Qu, K., Wan, B., Wang, K.C., Lei, M., and
Chang, H.Y. (2014). Essential role of lncRNA binding for WDR5 maintenance
of active chromatin and embryonic stem cell pluripotency. Elife 3, e02046.
Yildirim, E., Kirby, J.E., Brown, D.E., Mercier, F.E., Sadreyev, R.I., Scadden,
D.T., and Lee, J.T. (2013). Xist RNA is a potent suppressor of hematologic can-
cer in mice. Cell 152, 727–742.
Yu, L., Slovak, M.L., Mannoor, K., Chen, C., Hunger, S.P., Carroll, A.J.,
Schultz, R.A., Shaffer, L.G., Ballif, B.C., and Ning, Y. (2011). Microarray detec-
tion of multiple recurring submicroscopic chromosomal aberrations in pediat-
ric T-cell acute lymphoblastic leukemia. Leukemia 25, 1042–1046.
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D.,
Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012). The genetic basis of
early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163.
